.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Johnson and Johnson
Covington
Merck
QuintilesIMS
US Department of Justice
Mallinckrodt
Colorcon
Boehringer Ingelheim

Generated: June 25, 2017

DrugPatentWatch Database Preview

Rivastigmine tartrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for rivastigmine tartrate and what is the scope of rivastigmine tartrate freedom to operate?

Rivastigmine tartrate
is the generic ingredient in two branded drugs marketed by Novartis, Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, and Alembic Pharms Ltd, and is included in eleven NDAs. There is one patent protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for rivastigmine tartrate. Seventeen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: rivastigmine tartrate

Tradenames:2
Patents:1
Applicants:10
NDAs:11
Drug Master File Entries: see list32
Suppliers / Packagers: see list17
Bulk Api Vendors: see list72
Clinical Trials: see list212
Patent Applications: see list2,692
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:rivastigmine tartrate at DailyMed

Pharmacology for Ingredient: rivastigmine tartrate

Tentative approvals for RIVASTIGMINE TARTRATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe2MG/MLSOLUTION; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL077131-003Oct 22, 2007ABRXNoNo► Subscribe► Subscribe
Alembic Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL091689-003Jun 12, 2012ABRXNoNo► Subscribe► Subscribe
Cadila Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL203844-001Feb 13, 2017ABRXNoNo► Subscribe► Subscribe
Macleods Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL203148-002Aug 22, 2014ABRXNoNo► Subscribe► Subscribe
Orchid Hlthcare
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL090879-004Jun 10, 2015ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rivastigmine tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-004Apr 21, 20005,602,176► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-005Apr 21, 20005,602,176► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-006Apr 21, 20004,948,807► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-003Apr 21, 20004,948,807► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-005Apr 21, 20004,948,807► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Daiichi Sankyo
McKinsey
Cipla
Queensland Health
Express Scripts
Moodys
Boehringer Ingelheim
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot